|Ironshore to Present Three Posters at the 2019 Annual American Professional Society of ADHD and Related Disorders (APSARD) Meeting|
|Thursday, 10 January 2019 03:06|
Jan. 10, 2019 13:00 UTC
Ironshore to Present Three Posters at the 2019 Annual American Professional Society of ADHD and Related Disorders (APSARD) Meeting
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)-- Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and the global leader in the development of novel treatments for Attention Deficit Hyperactivity Disorder (ADHD), today announced it will present three posters at the 2019 Annual Meeting of The American Professional Society of ADHD and Related Disorders (APSARD) in Washington, D.C., January 18-20, 2019. Meeting attendees are also encouraged to visit Ironshore representatives at booth #4 to learn more about JORNAY PM™ (methylphenidate) which was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in patients 6 years and older. JORNAY PM is expected to be available commercially in the first half of this year.
“Ironshore is proud to attend this year’s APSARD meeting and have the opportunity to convene with healthcare professionals who focus exclusively on ADHD and related disorders,” said Dr. Randy Sallee, Chief Medical Officer of Ironshore Pharmaceuticals Inc. “Additionally, we look forward to presenting three posters to this distinguished group of specialists, including two posters related to the pivotal trial data that supported the recent FDA approval of JORNAY PM.”
JORNAY PM is the only stimulant medication that is dosed in the evening and has demonstrated improvement in the severity of ADHD symptoms in the early morning and throughout the day.
Following is a guide to Ironshore-sponsored data that will be presented during APSARD’s annual meeting:
JORNAY PM (methylphenidate HCl) (formerly known as HLD200)
Efficacy and Safety of DR/ER-MPH, a Delayed-Release and Extended-Release Methylphenidate, in Children with ADHD: Results from a Pivotal Phase 3 Classroom Trial
Improvements in At-Home Functional Impairment with DR/ER-MPH in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Post Hoc Analysis of BSFQ and PREMB-R by Norm-Referenced Cut-Offs
Sleep-Associated Adverse Events during Methylphenidate Treatment of Attention-Deficit/Hyperactivity Disorder in Youth: A Meta-Analysis
To schedule an interview with an investigator or Ironshore executive, please contact Mrs. Sarah Pierson at [email protected].
ADHD is among the most common childhood psychiatric conditions with behavioral symptoms fluctuating throughout the day. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors, or be overly active. Many home-based difficulties for children and adolescents with ADHD occur during the early morning routine (i.e. before the school day begins).
About JORNAY PM
JORNAY PM is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. JORNAY PM may help increase attention and decrease impulsiveness and hyperactivity in people 6 years of age and older with ADHD. It is not known if JORNAY PM is safe and effective in children under 6 years of age.
JORNAY PM is dosed once daily in the evening and should be initiated at 8:00 p.m. Timing of administration of JORNAY PM may be adjusted between 6:30 p.m. and 9:30 p.m. to optimize the tolerability and the efficacy the next morning and throughout the day. Please see additional dosing information in the full prescribing information for JORNAY PM at http://ironshorepharma.com/labeling.pdf.
IMPORTANT SAFETY INFORMATION
WARNING: ABUSE AND DEPENDENCE
CNS stimulants, including JORNAY PM, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
WARNINGS AND PRECAUTIONS
PREGNANCY AND LACTATION
Please see additional safety information in the full prescribing information for JORNAY PM at http://ironshorepharma.com/labeling.pdf.
About Ironshore Pharmaceuticals & Development, Inc.
Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a pharmaceutical company that is leveraging the proprietary drug delivery platform, DELEXIS®, to optimize the delivery of previously approved drug products. Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer and capital networks, and market intelligence to high-impact, Ontario, Canada-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies. For more information, visit Highlandtherapeutics.com.
This press release contains forward-looking information, which reflects Ironshore’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Ironshore’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Ironshore assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Ironshore Pharmaceuticals & Development, Inc.
Source: Ironshore Pharmaceuticals & Development, Inc.